Viatris
Search results
Mylan is now part of Viatris, a new company that aims to provide quality medicines for patients worldwide. Learn more about Viatris' vision, values and products on their website.
- Investors
Mylan is now part of Viatris, a new global healthcare...
- Stock Information
Stock Information - Mylan - Now a Part of Viatris
- News Archive
Mylan and Pfizer Receive Clearance from the U.S. Federal...
- Events & Presentations
The Investor Relations website contains information about...
- About The Offer
Forward-Looking Statements The communications on this...
- Mylan Sotradecol
Accessible through Mylan’s distributor, FFF Enterprises; How...
- Esomeprazole Magnesium Delayed
Mylan Esomeprazole Magnesium Delayed-release Capsules, USP:...
- Investors
Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and a "Global Center" in Canonsburg ...
Nov 12, 2019 · HERTFORDSHIRE, England & PITTSBURGH & Mylan N.V. (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) today announced that the name of the new company to be formed by the planned combination of Mylan and Upjohn, a division of Pfizer, will be Viatris (pronounced ‘viǝ-trīs).
Viatris is a global pharmaceutical company that believes in healthcare not as it is, but as it should be. Learn about our story, explore our products and browse career opportunities.
Viatris is a global healthcare company that was formed by the combination of Mylan and Upjohn in 2020. Learn about the history, vision and mission of both Mylan and Upjohn, and how they evolved to become Viatris.
Mylan markets high quality API and ARV products in India and around the world. It also collaborates with Sesame Workshop and provides medical equipment and support for COVID-19 care and education.
Jul 29, 2019 · HERTFORDSHIRE, England & PITTSBURGH & Mylan N.V. (Nasdaq: MYL) and Pfizer Inc. (NYSE: PFE) today announced a definitive agreement to combine Mylan with Upjohn, Pfizer’s off-patent branded and generic established medicines business, creating a new global pharmaceutical company.
